Sydney Australia, 27 November 2025: Recce Pharmaceuticals Limited (ASX:RCE, FSE:R9Q), (Recce or the Company) a leading developer of a New Class of Synthetic Anti-Infectives, is pleased to announce the Hong Kong Special Administrative Region has formally granted Patent Family 4 for Recce’s Anti-Infectives, expiry 2041. The Hong Kong Patent claims relate to RECCE® 327 (R327) and RECCE® 529 (R529), most notably: - Process for preparation of RECCE® anti-infectives- Use of R327/R529 for the treatment of disease, ...
[ more ]
